Verition Fund Management
NGNE icon

Verition Fund Management’s Neurogene NGNE Stock Holding History

Verition Fund Management’s Portfolio NGNE Stock Details NGNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-1,272
Closed -$313K – 2045
2021
Q1 		$313K Buy
1,272
+5
+0.4% +$1.28K ﹤0.01% 1099
2020
Q4 		$357K Buy
+1,267
New +$310K ﹤0.01% 773

Other funds holding NGNE

RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
PAMU
Pictet Asset Management (UK) London, United Kingdom $91.8B AUM 47.77% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Verition Fund Management's NGNE Position: Q2 2021 in Review

Verition Fund Management sold out of Neurogene (NGNE) in Q2 2021, closing a stake of 1,272 shares — an estimated $313K sold.

Verition Fund Management first reported a position in NGNE in Q4 2020 and held it in 2 quarters. The position peaked at $357K in Q4 2020. 82 funds tracked by Wall St. Rank hold NGNE as of Q2 2021.

  • Verition Fund Management reported no remaining Neurogene position as of Q2 2021 after selling out during the quarter.
  • Verition Fund Management sold 1,272 Neurogene shares in Q2 2021, an estimated $313K.
  • Verition Fund Management first reported a position in Neurogene in Q4 2020 and held it in 2 quarters.
  • Verition Fund Management's Neurogene position peaked at $357K in Q4 2020.
  • 82 funds tracked by Wall St. Rank held Neurogene as of Q2 2021.

Based on Verition Fund Management's 13F filing for Q2 2021, filed 16 Aug 2021.